https://www.nasdaq.com/press-release/alligator-bioscience-aptevo-therapeutics-announce-co-publication-in-peer-reviewed-0
https://www.nasdaq.com/press-release/alligator-bioscience-aptevo-therapeutics-announce-co-publication-in-peer-reviewed
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-first-complete-remission-providing-clinical-update-for
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-the-presentation-of-two-abstracts-at-the-upcoming
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-third-quarter-financial-results-with-business-highlights
https://www.nasdaq.com/press-release/alligator-bioscience-and-aptevo-therapeutics-announce-a-poster-presentation-of-alg
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-preclinical-data-for-bispecific-antibody-apvo603-at-the
https://www.nasdaq.com/press-release/aptevo-therapeutics-presents-promising-clinical-data-on-its-lead-leukemia-drug
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-in-the-refereed-medical-journal-cancers-that-the-risk-of
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-publication-of-a-scientific-article-in-peer-reviewed
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-apvo436-monotherapy-is-active-in-patients-who-have
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-second-quarter-financial-results-with-business-highlights
https://www.nasdaq.com/press-release/aptevo-therapeutics-chief-scientific-officer-jane-gross-phd-to-present-at-upcoming
https://www.nasdaq.com/press-release/aptevo-therapeutics-scientists-to-present-at-virtual-cell-engager-summit-2021-06-30
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-inclusion-in-the-russell-microcapr-index-2021-06-29
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-expansion-phase-of-lead-anti-leukemia-drug-apvo436-in
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-positive-phase-1-clinical-data-for-its-lead-leukemia-drug
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-first-quarter-2021-financial-results-2021-05-12
https://www.nasdaq.com/press-release/aptevo-therapeutics-to-present-at-the-american-association-for-cancer-research
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-2020-financial-results-and-provides-business-update-2021
https://www.nasdaq.com/press-release/aptevo-confirms-receipt-of-nominations-and-proposal-notice-2021-02-09
https://www.nasdaq.com/press-release/aptevo-therapeutics-provides-update-on-ongoing-apvo436-phase-1-clinical-trial-2021-01
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-the-launch-of-its-second-platform-technology-adaptir
https://www.nasdaq.com/press-release/aptevo-confirms-receipt-of-unsolicited-indication-of-interest-2020-11-19
https://www.nasdaq.com/press-release/aptevo-therapeutics-and-alligator-bioscience-advancing-the-bispecific-4-1bbx5t4-0
https://www.nasdaq.com/press-release/aptevo-therapeutics-and-alligator-bioscience-advancing-the-bispecific-4-1bbx5t4
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-third-quarter-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aptevo-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancers-sitc-35th
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-second-complete-remission-in-ongoing-apvo436-phase-1
https://www.nasdaq.com/press-release/aptevo-therapeutics-adopts-limited-duration-stockholder-rights-plan-2020-11-08
https://www.nasdaq.com/press-release/aptevo-therapeutics-announces-first-complete-remission-in-ongoing-apvo436-phase-1
https://www.nasdaq.com/press-release/aptevo-therapeutics-provides-update-on-ongoing-apvo436-phase-1-clinical-trial-2020-09
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-second-quarter-2020-financial-results-2020-08-14
https://www.nasdaq.com/press-release/aptevo-therapeutics-secures-%2425-million-non-dilutive-financing-from-midcap-financial
https://www.nasdaq.com/press-release/aptevo-therapeutics-engages-piper-sandler-to-sell-its-ruxiencer-and-ixinityr-royalty
https://www.nasdaq.com/press-release/aptevo-therapeutics-collects-%24750000-working-capital-escrow-from-medexus-related-to
https://www.nasdaq.com/press-release/aptevo-therapeutics-to-receive-seven-year-quarterly-royalty-payment-stream-from
https://www.nasdaq.com/press-release/aptevo-therapeutics-and-alligator-bioscience-present-new-preclinical-data-for-alg-1
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-first-quarter-2020-financial-results-2020-05-13
https://www.nasdaq.com/press-release/aptevo-therapeutics-regains-compliance-with-nasdaq-listing-requirements-2020-04-14
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-2019-financial-results-and-provides-business-update-2020
https://www.nasdaq.com/press-release/aptevo-therapeutics-provides-update-on-ongoing-apvo436-phase-1-clinical-trial-2020-03
https://www.nasdaq.com/press-release/aptevo-therapeutics-sells-ixinity-hemophilia-b-therapy-for-estimated-proceeds-in
https://www.nasdaq.com/press-release/aptevo-therapeutics-doses-first-patient-in-ixinity-clinical-trial-for-potential
https://www.nasdaq.com/press-release/aptevo-therapeutics-receives-orphan-drug-designation-for-apvo436-for-the-treatment-of
https://www.nasdaq.com/press-release/aptevo-therapeutics-and-alligator-bioscience-present-new-preclinical-data-for-alg-0
https://www.nasdaq.com/press-release/aptevo-therapeutics-reports-third-quarter-2019-financial-results-2019-11-07
https://www.nasdaq.com/press-release/aptevo-therapeutics-provides-corporate-and-pipeline-update-2019-10-03
